



## **Exercise rate of 98.8 percent for SpectraCure's warrants (TO3)**

On 29 November, SpectraCure AB (publ) ("SpectraCure") ended the exercise period for the Series 3 TO3 B subscription warrants.

In total, 5,828,739 shares have been subscribed during the now concluded exercise period. SpectraCure is thus provided MSEK 37.9 in proceeds, before issuance costs to the estimated amount of MSEK 1.1. The exercise rate was 98.8 percent.

As soon as the proceeds from all of the newly subscribed shares (interim shares) have been received by the company, and the issue has been finally registered with the Swedish Companies Registration Office, the interim shares will be automatically converted to regular shares without further notice to the holders. This is projected to take place in week 51.

Through the exercise of warrants, the number of shares outstanding in SpectraCure increases by 5,828,739, to 87,465,566 shares in total. Simultaneously, the share capital increases by SEK 582,873.90, to SEK 8,746,556.60.

"The outcome is very satisfactory, and I consider this to be a confirmation that we continue to have the confidence of the shareholders. The proceeds from the issue ensures our estimated capital requirements for the continuation of the clinical trial, and we are looking forward to the result," says Masoud Khayyami, CEO.

G&W Fondkommission has acted as financial adviser and Advokatfirman Lindahl has acted as legal adviser to SpectraCure in connection with the transaction.

### **For more information, please contact:**

SpectraCure AB (publ), CEO, Masoud Khayyami, telephone: +46(0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: [ca@gwkapital.se](mailto:ca@gwkapital.se), telephone: +46(0) 8 503 000 50

This information is information that SpectraCure AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, on December 4, 2019, at 09:15 a.m.

### **SpectraCure in short**

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT. PDT a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region.